31 – 45 of 49
- show: 15
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2007
-
Mark
Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation
(
- Contribution to journal › Article
-
Mark
The risk associated with indwelling catheters in children with haemophilia.
(
- Contribution to journal › Scientific review
-
Mark
Human Plasma von Willebrand Factor/Factor VIII Complex (Haemate((R)) P/Humate-P((R))) in von Willebrand Disease and Haemophilia A: A Viewpoint by Eric Berntorp.
(
- Contribution to journal › Letter
- 2006
-
Mark
Practice patterns in haemophilia A therapy - global progress towards optimal care
(
- Contribution to journal › Article
- 2005
-
Mark
Changing pattern of care of boys with haemophilia in western European centres
(
- Contribution to journal › Article
- 2004
-
Mark
Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A
(
- Contribution to journal › Article
- 2003
-
Mark
Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay
(
- Contribution to journal › Article
- 2002
-
Mark
Inhibitors in the Swedish population with severe haemophilia A and B : A 20-year survey
(
- Contribution to journal › Article
- 1999
-
Mark
Origin of mutation in sporadic cases of haemophilia A
(
- Contribution to journal › Article
-
Mark
Prenatal diagnosis of haemophilia
(
- Contribution to journal › Scientific review
- 1998
-
Mark
Prophylactic treatment in Sweden - Overtreatment or optimal model?
(
- Contribution to journal › Article
-
Mark
Can haemophilic arthropathy be prevented?
(
- Contribution to journal › Special issue (editor)
-
Mark
Port-A-Cath usage in children with haemophilia : Experience of 53 cases
(
- Contribution to journal › Article
- 1997
-
Mark
Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A
(
- Contribution to journal › Article
-
Mark
Pharmacokinetic dosing of factor VIII and factor IX in prophylactic treatment of haemophilia
1997)(
- Thesis › Doctoral thesis (compilation)